Clinical Roundup

The gains in insurance coverage with the Patient Protection and Affordable Care Act have translated into improved health for young women with gynecologic cancers, who are getting diagnosed at earlier stages of their disease because of ACA benefits, a study by Johns Hopkins Medicine found.

Takeda Pharmaceutical Co. Ltd. announced the randomized, phase III TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral Ninlaro (ixazomib) as a maintenance therapy resulted in a statistically significant improvement in progression-free survival versus placebo.

A study by researchers from the International Agency for Research on Cancer, published in JAMA Oncology, demonstrates that a blood test measuring four protein biomarkers can improve the identification of individuals who would later develop lung cancer.

Genentech, a member of the Roche Group, announced that phase III IMpassion130 study met its co-primary endpoint of progression free survival.

According to data presented by NewLink, all 10 newly diagnosed DIPG patients in a phase I study demonstrated initial symptomatic improvement after treatment with indoximod and chemotherapy.

AstraZeneca and Merck announced positive results from the randomized, double-blind, placebo-controlled, phase III SOLO-1 trial of Lynparza (olaparib) tablets.

Genentech said that the phase III IMpower133 study met its co-primary endpoints of overall survival and progression-free survival at its first interim analysis.

Taiho Oncology Inc. and Servier announced clinical data from the pivotal phase III trial (TAGS) evaluating LONSURF (trifluridine and tipiracil, TAS-102) plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated metastatic gastric cancer refractory to standard therapies.

To ensure the well-being and safety of healthcare providers and patients, the Oncology Nursing Society developed the Toolkit for Safe Handling of Hazardous Drugs for Nurses in Oncology.